Results 251 to 260 of about 28,823 (297)
Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties [PDF]
Expert Opinion on Investigational Drugs, 2006 Vildagliptin is a competitive and reversible inhibitor of dipeptidyl peptidase-4. Dipeptidyl peptidase-4 inhibitors act mainly by preventing the rapid degradation of glucagon-like peptide-1. In clinical trials, vildagliptin improves glycaemic control both as monotherapy and in combination with metformin for periods of < or = 52 weeks in subjects with ...
Ahrén, Bo
core +5 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Dipeptidyl peptidase-4 inhibitors
Reactions Weekly, 2021The dipeptidyl peptidase 4 (DPP-4) inhibitor has become a popular anti-diabetes medication since its introduction in 2006. They are small molecules that specifically bind to the catalytic domain of DPP-4, which consequently prevents the enzymatic inactivation of incretin hormones (glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide)
Yoo Hyung Kim, Young Min Cho
openaire +2 more sources
Effect of dipeptidyl peptidase‐4 inhibitors on complement activation
Diabetes/Metabolism Research and Reviews, 2020AbstractBackgroundAdverse activation of the complement cascade in the innate immune system appears to be involved in development of vascular complications in diabetes. Dipeptidyl peptidase‐4 (DPP‐4) is a cell surface serine protease expressed in a variety of tissues.
Ingeborg T. Hoffmann‐Petersen +7 more
openaire +3 more sources
Pharmacology of Dipeptidyl Peptidase-4 Inhibitors
Drugs, 2011The dipeptidyl peptidase (DPP)-4 inhibitors, which enhance glucose-dependent insulin secretion from pancreatic β cells by preventing DPP-4-mediated degradation of endogenously released incretin hormones, represent a new therapeutic approach to the management of type 2 diabetes mellitus. The 'first-in-class' DPP-4 inhibitor, sitagliptin, was approved in
R. Baetta, A. Corsini
openaire +2 more sources
Renal outcomes with dipeptidyl peptidase-4 inhibitors
Diabetes & Metabolism, 2018Dipeptidyl peptidase-4 inhibitors (DPP-4is) are increasingly being used in the management of type 2 diabetes (T2D). The present review summarizes the current knowledge of the effects of DPP-4is on renal outcomes by analyzing the experimental preclinical data, the effects of DPP-4is on urinary albumin-creatinine ratios (UACRs) and estimated glomerular ...
Scheen, André, DELANAYE, Pierre
openaire +3 more sources
Tolerability of Dipeptidyl Peptidase-4 Inhibitors: A Review
Clinical Therapeutics, 2011Oral glucose-lowering agents are used to treat patients with type 2 diabetes mellitus (T2DM). Most patients require multiple agents to maintain glycemic targets. Dipeptidyl peptidase-4 (DPP-4) inhibitors are administered as monotherapy and in combination therapy for the treatment of T2DM.The aim of this article was to provide a thorough review of ...
Kathleen R, Richard +2 more
openaire +2 more sources
The effects of dipeptidyl peptidase‐4 inhibitors on kidney outcomes
Diabetes, Obesity and Metabolism, 2020Abstract Aims To summarize evidence from randomized controlled trials (RCTs) concerning the effects of dipeptidyl peptidase‐4 (DPP‐4) inhibitors on kidney outcomes in patients with type 2 diabetes mellitus (T2DM). Methods
Daniel V. O'Hara +5 more
openaire +2 more sources
Dipeptidyl peptidase-4 inhibitors as new tools for cardioprotection
Heart Failure Reviews, 2020Previous studies have demonstrated that individuals with type 2 diabetes mellitus (T2DM) have a two- to fourfold propensity to develop cardiovascular disease (CVD) than nondiabetic population, making CVD a major cause of death and disability among people with T2DM.
Marina, Rankovic +8 more
openaire +2 more sources
Dipeptidyl peptidase-4 inhibitors
2016Dipeptidyl peptidase (DPP)-4 inhibitors inhibit the activity of the enzyme responsible for the initial rapid degradation of the incretin hormones, thereby enhancing their antihyperglycemic effects.
openaire +1 more source